Company Profile

ALEMBIC PHARMACEUTICALS LTD.

NSE : APLLTDBSE : 533573ISIN CODE : INE901L01018Industry : Pharmaceuticals & DrugsHouse : Alembic
BSE1005.251.55 (+0.15 % )
PREV CLOSE (Rs.) 1003.70
OPEN PRICE (Rs.) 1015.00
BID PRICE (QTY) 1005.05 (67 )
OFFER PRICE (QTY) 1006.30 (33 )
VOLUME 9536
TODAY'S LOW / HIGH (Rs.)1002.70 1018.30
52 WK LOW / HIGH (Rs.)641.55 1150
NSE1005.80 0.9 (+0.09 % )
PREV CLOSE(Rs.) 1004.90
OPEN PRICE (Rs.) 1013.00
BID PRICE (QTY) 1005.80 (600 )
OFFER PRICE (QTY) 1006.25 (16 )
VOLUME 231845
TODAY'S LOW / HIGH(Rs.) 1001.15 1018.10
52 WK LOW / HIGH (Rs.)640.75 1145

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.99
TTM EPS (Rs.) 64.03
P/E Ratio 15.72
Book Value (Rs.) 241.17
Face Value (Rs.) 2
MCap (Rs. in Mn) 197850.61
Price/Earning (TTM) 14.08
Price/Sales (TTM) 4.00
Price/Book (MRQ) 4.17
PAT Margin (%) 23.46
ROCE (%) 27.08
Incorporation Year : 2010

Management Info :

Chirayu Amin - Chairman Shaunak Amin - Managing Director

Registered Office :

Address : Alembic Road, , ,
Vadodara,
Gujarat-390003

Phone : 0265 - 2280550 , 2280880

Registrar's Details : Link Intime India Pvt Ltd.
B-102 & B103, Shangrila Complex, First Floor,Opp: HDFC Bank, Near Radhakrishna Char Rasta,Akota,Vadodara
Listing : BSE, NSE, MCX
NEWS More
23Apr04-23-2021$Alembic Pharmaceuticals gets USFDA’s final nod for Doxepin Hydrochloride Capsules Alembic Pharmaceuticals gets

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Sinequan Capsules 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, of Pfizer Inc. (Pfizer).

Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg have an estimated market size of $ 41 million for twelve months ending December 2020. Alembic has a cumulative total of 141 ANDA approvals (124 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharmaceuticals has received final approval from the US..
23Apr04-23-2021$Alembic Pharmaceuticals informs about press release Alembic Pharmaceuticals info

Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg. In this regard, the company has enclosed a press release on 23rd April 2021.

The above information is a part of company’s filings submitted to BSE.





Alembic Pharmaceuticals has informed the exchange that the Comp..
23Apr04-23-2021$Alembic Pharmaceuticals jumps on getting USFDA’s final nod for Doxepin Hydrochloride Capsules Alembic Pharmaceuticals jump

Alembic Pharmaceuticals is currently trading at Rs. 1011.40, up by 7.70 points or 0.77% from its previous closing of Rs. 1003.70 on the BSE.

The scrip opened at Rs. 1015.00 and has touched a high and low of Rs. 1018.30 and Rs. 1002.70 respectively. So far 8750 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1150.00 on 18-Dec-2020 and a 52 week low of Rs. 641.55 on 23-Apr-2020.

Last one week high and low of the scrip stood at Rs. 1048.00 and Rs. 974.50 respectively. The current market cap of the company is Rs. 19821.43 crore.

The promoters holding in the company stood at 69.48%, while Institutions and Non-Institutions held 17.53% and 12.99% respectively.

Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Sinequan Capsules 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, of Pfizer Inc. (Pfizer).

Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg have an estimated market size of $ 41 million for twelve months ending December 2020. Alembic has a cumulative total of 141 ANDA approvals (124 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharmaceuticals is currently trading at Rs. 1011.40, up..
22Apr04-22-2021$Alembic Pharmaceuticals informs about loss of share certificates Alembic Pharmaceuticals info

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Alembic Pharmaceuticals has informed that the share certificate(s) of the Company has been reported as lost/ misplaced and the legal heir(s) of registered shareholder(s) have requested the Company for issue of duplicate share certificate. The Company enclosed an e-mail intimation received from Link Intime India, Registrar and Share Transfer Agent giving the proof of the date of receipt of aforesaid information by the Company.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 39(3) of the SEBI (Listing Obligations a..
08Apr04-08-2021$Alembic Pharmaceuticals surges as its JV gets tentative approval for Efinaconazole Topical Solution Alembic Pharmaceuticals surg

Alembic Pharmaceuticals is currently trading at Rs. 985.00, up by 11.75 points or 1.21% from its previous closing of Rs. 973.25 on the BSE.

The scrip opened at Rs. 983.95 and has touched a high and low of Rs. 1005.30 and Rs. 982.75 respectively. So far 12707 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1150.00 on 18-Dec-2020 and a 52 week low of Rs. 600.00 on 21-Apr-2020.

Last one week high and low of the scrip stood at Rs. 1005.30 and Rs. 945.30 respectively. The current market cap of the company is Rs. 19493.17 crore.

The promoters holding in the company stood at 69.78%, while Institutions and Non-Institutions held 17.10% and 13.12% respectively.

Alembic Pharmaceuticals’ joint venture (JV) -- Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Efinaconazole Topical Solution, 10%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Jublia Topical Solution, 10%, of Bausch Health Americas, Inc. (Bausch). Efinaconazole Topical Solution, 10% is indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.

Efinaconazole Topical Solution, 10% has an estimated market size of $ 233 million for twelve months ending December 2020. Aleor has settled the case with Bausch Health and. will launch its generic as per the terms of settlement. Alembic has a cumulative total of 140 ANDA approvals (123 final approvals and 17 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharmaceuticals is currently trading at Rs. 985.00, up..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit2773.59694
Gross Profit 3340.4 11668
Operating Profit 3744.613376.5
Net Sales 12357.741325.5
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
TTK Healthcare (BSE)
 706.00 (15.36%)
M.Cap ( in Cr)
1003.25
Orchid Pharma (BSE)
 1623.40 (5.00%)
M.Cap ( in Cr)
6626.13
Astrazeneca Pharma I (BSE)
 4344.95 (1.20%)
M.Cap ( in Cr)
10865.25
Gland Pharma (BSE)
 2697.10 (1.47%)
M.Cap ( in Cr)
44242.89
Panacea Biotec (BSE)
 349.95 (8.11%)
M.Cap ( in Cr)
2136.73
Shareholding Pattern More
PROMOTERS 69.48 %
FI/BANKS/INSURANCE 6.59 %
MUTUAL FUNDS/UTI 4.34 %
NON-INSTITUTION 12.99 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes